RANKL has been identified to affect the immune system and control bone regeneration and remodeling. RANKL is an apoptosis regulator gene, a binding partner of osteoprotegerin (OPG), a ligand for the receptor RANK and controls cell proliferation by modifying protein levels of Id4, Id2 and cyclin D1.
Herein, do osteoclasts have RANKL receptors?
Osteoclasts are bone-resorbing cells that are derived from hematopoietic precursor cells and require macrophage-colony stimulating factor and receptor activator of nuclear factor-κB ligand (RANKL) for their survival, proliferation, differentiation, and activation.
Beside this, does OPG bind to RANK or RANKL?
Osteoprotegerin (OPG) is secreted by osteoblasts and osteogenic stromal stem cells and protects the skeleton from excessive bone resorption by binding to RANKL and preventing it from interacting with RANK.
Is RANK ligand on osteoblast?
RANKL is expressed on osteoblasts and T cells. It binds the receptor RANK, which is produced on osteoclasts and their progenitors. The interaction of RANK with RANKL is required for osteoclast formation, differentiation, activation and survival.
What cell type makes RANK?
RANK is mainly expressed in osteoclast precursors, mature osteoclasts, and immune cells such as DCs, macrophages, and microglia. A recent study demonstrated that the osteoclast releases RANK-expressing extracellular vesicles, which interact with the RANKL on osteoblasts.
What does RANK do in osteoporosis?
The interaction of RANK with its ligand (RANKL) has been identified as the final common pathway through which bone resorption is regulated [29]. By binding to its receptor RANK on osteoclastic precursors, RANKL controls the differentiation, proliferation, and survival of osteoclasts.
What does rank ligand stand for?
What is RANK Ligand inhibitor?
RANKL inhibitors are used to treat osteoporosis, breast cancer, lung cancer, and prostate cancer. They work by preventing bone fractures and by destroying cancer cells.
What is RANKL OPG ratio?
OPG protects the skeleton from excessive bone resorption by binding to RANKL and preventing it from binding to its receptor, RANK. Thus, RANKL/OPG ratio is an important determinant of bone mass and skeletal integrity.
What is the difference between RANKL and RANK?
RANK is the receptor for RANK-Ligand (RANKL) and part of the RANK/RANKL/OPG signaling pathway that regulates osteoclast differentiation and activation. It is associated with bone remodeling and repair, immune cell function, lymph node development, thermal regulation, and mammary gland development.
What stimulates RANK Ligand?
RANKL expression is stimulated in osteoblast/stromal cells by most of the factors that are known to stimulate osteoclast formation and activity. It is highly expressed in lymph nodes, thymus and lung, and at low levels in a variety of other tissues including spleen and bone marrow [17].
What type of molecule is RANKL?
RANKL is a transmembrane molecule expressed by mesenchymal cell and lymphocytes. The soluble form of RANKL is a consequence of proteolytic cleavage. RANKL binds to RANK on hematopoietic cells and activates cytoplasmic adaptor proteins (e.g., tumor necrosis factor receptor-associated factor 6, TRAF6).
When RANKL binds to RANK what occurs?
RANKL is a transmembrane molecule expressed by mesenchymal cell and lymphocytes. The soluble form of RANKL is a consequence of proteolytic cleavage. RANKL binds to RANK on hematopoietic cells and activates cytoplasmic adaptor proteins (e.g., tumor necrosis factor receptor-associated factor 6, TRAF6).
Where is the RANK Ligand?
RANK ligand (RANKL), a key mediator of bone resorption in normal and pathological states, is expressed as membrane-bound or soluble forms by tissues as diverse as lymph nodes, spleen, thymus and bone-forming cells.